SBRT vs. Conventional Fractionation With HDR Boost for Prostate Cancer

Titre officiel

A Randomized Feasibility Trial of Stereotactic Body Radiation Therapy Versus Conventional Fractionation With High Dose-rate (HDR) Brachytherapy Boost for Prostate Cancer

Sommaire:

Répartition aléatoire entre la RTSC et le complément de dose d’irradiation fractionné classique après une curiethérapie à haut débit de dose (HDD) pour le cancer de la prostate.

Description de l'essai

Primary Outcome:

• Treatment Feasibility

Secondary Outcome:

• QOL
• Treatment Toxicity
• Cumulative biochemical failure
• Overall Survival
• Cancer Free Survival
• Metastasis Free Survival
• Freedom From Local Failure
• Freedom From Regional Failure
• ADT Free Survival
• PSA nadir

Many treatment options exist for prostate cancer. One common treatment approach is to combine high-dose rate (HDR) brachytherapy (temporary insertion of radiation into the prostate) and external beam radiation. External beam radiation typically requires daily radiation treatment for three to five weeks. Improvements to radiation planning and delivery has allowed stereotactic body radiation therapy (SBRT) to be implemented in many types of cancer. SBRT has been implemented as a standard treatment option after HDR brachytherapy in response to the COVID pandemic. We are seeking to evaluate whether it is feasible to randomly assign men between SBRT (which will be five treatments of radiation or conventional radiation (3-5 weeks of daily treatment) following HDR brachytherapy

Voir cet essai sur ClinicalTrials.gov